Q3 2025 Esperion Therapeutics Inc Earnings Call Transcript

Nov 6, 2025 / 01:00 PM GMT

Release Date Price: $2.5 (-14.97%)

Transcript 10-Q8-K

Key Points

Positve

Esperion Therapeutics Inc (ESPR) reported a 69% year-over-year increase in total revenue for Q3 2025, reaching $87.3 million.
US net product revenue grew by 31% year-over-year to $40.7 million, indicating strong domestic performance.
The company finalized agreements with four generic manufacturers to delay the marketing of generic versions of their products until April 2040, supporting long-term value.
Esperion's benpetoic acid products were included in the ESC EAS guidelines, validating their clinical benefit and signaling potential for expanded use.
The company achieved an 87% average approval rate for Medicare coverage, with significant reductions in out-of-pocket costs for patients.

Negative

Sequential growth was impacted by one-time costs related to enhanced patient access programs.
Research and development expenses increased by 36% year-over-year, reaching $14.1 million.
Selling, general, and administrative expenses rose by 5% year-over-year, primarily due to increased legal and media costs.
Despite a 9% increase in total retail prescription equivalents, US revenues were fairly flat due to one-time investments.
The company incurred one-time costs to secure enhanced coverage with major Medicare providers, impacting short-term financials.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ESPR.OQ - Esperion Therapeutics Inc
Q3 2025 Esperion Therapeutics Inc Earnings Call
Nov 06, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello ladies and gentlemen, and thank you for standing by. Welcome to Experian 3rd quarter 2025 financial results. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Alina Vanessa, head of investor relations for Experian Therapeutics. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good morning and welcome to Experian's 3rd quarter 2025

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.